HomeChatAlertsCalendarScreenerWatchlistsFiles
Docs
Sign upJoinLog inLogin

Allarity Therapeutics, Inc. (ALLR) stock profile

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor for treating renal cell carcinoma; IXEMPRA, a microtubule inhibitor for metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Key facts

SymbolALLR
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOThomas H. Jensen
Employees6
HeadquartersBoston, MA, US
IPO2021-12-21
Websitewww.allarity.com

Explore ALLR on Vantafin

  • Allarity Therapeutics, Inc. Overview
  • Allarity Therapeutics, Inc. Financials
  • Allarity Therapeutics, Inc. News
  • Allarity Therapeutics, Inc. Events
  • Allarity Therapeutics, Inc. SEC filings
  • Allarity Therapeutics, Inc. Insider transactions
  • Allarity Therapeutics, Inc. Transcripts

Frequently asked questions

What does Allarity Therapeutics, Inc. (ALLR) do?
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor for treating renal cell carcinoma; IXEMPRA, a microtubule inhibitor for metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Where is ALLR stock listed?
Allarity Therapeutics, Inc. trades under the ticker ALLR on NASDAQ.
How can I research ALLR's financials and filings?
Vantafin provides Allarity Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ALLR profile.